secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0000950170-22-014777
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences reports Q2 net loss of $15.1M; FDA clears IND for TYRA-300
---------------------------------------------------------------------------

- Q2 2022 net loss $15.1M vs $5.5M in Q2 2021; R&D expense $12.0M vs $4.4M.
- Cash and cash equivalents $275.1M as of June 30, 2022, sufficient to fund operations.
- FDA cleared IND for TYRA-300 (FGFR3 inhibitor) to begin Phase 1/2 SURF301 study in metastatic urothelial carcinoma.
- IND for TYRA-200 (FGFR2 inhibitor) on track for submission in 2H 2022 with initial focus on intrahepatic cholangiocarcinoma.
- Key leadership hires: Sarah Honig (VP Corp Dev) and Ali Fawaz (General Counsel/Secretary).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000095017022014777/0000950170-22-014777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000095017022014777/tyra-20220804.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-014777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer